Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 20.05% is 38% above its 5-year average of 14.51%, near the high end of its 5-year range (1.93%–20.67%).
0.32% below its 12-month average of 20.12%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 4.54%.
RETURN ON ASSETS (ROA)
20.05%
RETURN ON ASSETS (ROA) AVG TTM
20.12%
RETURN ON ASSETS (ROA) AVG 3Y
18.47%
RETURN ON ASSETS (ROA) AVG 5Y
14.51%
RETURN ON ASSETS (ROA) AVG 10Y
14.23%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.32%
CURRENT VS 3Y AVG
+8.54%
CURRENT VS 5Y AVG
+38.16%
CURRENT VS 10Y AVG
+40.88%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.29%
median of 683 covered companies
CURRENT VS SECTOR MEDIAN
+166.19%
vs the sector median at left
IRadimed Corporation
Market Cap
$1.08B
Return on Assets (ROA)
20.05%
TTM Avg
20.12%
3Y Avg
18.47%
5Y Avg
14.51%
Market Cap
$1.07B
Return on Assets (ROA)
-56.27%
TTM Avg
-37.98%
3Y Avg
-21.94%
5Y Avg
-21.15%
Market Cap
$1.11B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
-157.70%
Market Cap
$1.06B
Return on Assets (ROA)
-10.18%
TTM Avg
-8.89%
3Y Avg
-12.61%
5Y Avg
-16.81%
Market Cap
$1.06B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$1.04B
Return on Assets (ROA)
-3.46%
TTM Avg
-0.37%
3Y Avg
-7.11%
5Y Avg
-6.26%
Market Cap
$1.13B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.13B
Return on Assets (ROA)
4.50%
TTM Avg
8.06%
3Y Avg
9.38%
5Y Avg
7.83%
Market Cap
$1.03B
Return on Assets (ROA)
-43.17%
TTM Avg
-16.38%
3Y Avg
-11.13%
5Y Avg
-30.16%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IRadimed Corporation (IRMD) | $1.08B | 20.05% | 20.12% | 18.47% | 14.51% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.07B | -56.27% | -37.98% | -21.94% | -21.15% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.11B | -36.19% | -21.98% | -157.70% | -157.70% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.06B | -10.18% | -8.89% | -12.61% | -16.81% |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | -6.43% | -17.46% | -82.63% | -55.94% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | -3.46% | -0.37% | -7.11% | -6.26% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -8.93% | -2.89% | -5.64% | -7.78% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 4.50% | 8.06% | 9.38% | 7.83% |
| Immatics N.V. (IMTX)vs › | $1.03B | -43.17% | -16.38% | -11.13% | -30.16% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | -0.20% | -7.25% | -2.02% | 0.01% |
ROA
20.1%
ROE
22.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 20.67% |
| 2024-12-31 | 19.56% |
| 2023-12-31 | 18.66% |
| 2022-12-31 | 15.00% |
| 2021-12-31 | 11.25% |
| 2020-12-31 | 1.93% |
| 2019-12-31 | 14.43% |
| 2018-12-31 | 13.01% |
| 2017-12-31 | 1.28% |
| 2016-12-31 | 19.40% |
| 2015-12-31 | 21.36% |
| 2014-12-31 | 8.80% |
| 2013-12-31 | 27.72% |
| 2012-12-31 | 17.39% |
